

Expression profiles of circRNAs and identification of hsa_circ_0007608 and hsa_circ_0064656 as potential biomarkers for COPD-PH patients

Jinyan YU^{1#}, Shulun HUANG^{1#}, Weiyu SHEN^{1#}, Zheming ZHANG¹, Shugao YE², Yuan

CHEN², Yue YANG³, Tao BIAN³, Yan WU³

¹Wuxi Clinical Medical College of Nanjing Medical University, Wuxi, Jiangsu, 214023, People's Republic of China; ²Transplant Centre, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu, 214023, People's Republic of China; ³Department of Respiratory Medicine, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu, 214023, People's Republic of China

Jinyan YU, Shulun HUANG, Weiyu SHEN contributed equally to this work

Correspondence: Yan WU, Tao BIAN, Department of Respiratory Medicine, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu, 214023, People's Republic of China, Email: wuyanphd@163.com; btaophd@sina.com.

Abstract

Pulmonary hypertension(PH) is a common complication of chronic obstructive pulmonary disease(COPD) which can worsen the prognosis and increase the mortality of COPD patients. However, the underlying mechanisms of PH in COPD(COPD-PH) remain to be elucidated. This study is the first to explore the expression profile of circRNAs in human lung tissues with definite diagnosis of COPD-PH and validate the differentially expressed circRNAs(DECs) utilizing human serum, pulmonary arterial endothelial cells(HPAECs) and pulmonary arterial smooth muscle cells(HPASMCs). A total of 136 circRNAs(39 up-regulated and 97 down-regulated) were differentially expressed between the COPD-PH group and the control group. Following quantitative real-time polymerase chain reaction(qRT-PCR) validation, two circRNAs (hsa_circ_0007608 and hsa_circ_0064656) were believed to be involved in the pathogenesis. GO and KEGG pathway analysis suggested these two DECs were mainly related to the cellular proliferation, migration and EndoMT. PPI network revealed 11 pairs of key mRNAs. VCAM1, VCAN and THBS1, three hub mRNAs with the highest reliability among all, were validated and

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. proven to be up-regulated in COPD-PH. We innovatively found that VCAN may be involved in

COPD-PH. These identified genes show high potential to be diagnostic markers and therapeutic targets of COPD-PH, and may provide new insights into the underlying mechanisms of COPD-PH patients.

Keywords: pulmonary hypertension in chronic obstructive pulmonary disease(COPD-PH); circular RNA(circRNA); RNA-sequencing (RNA-Seq); Biomarker;

Introduction

Pulmonary hypertension(PH) is a common complication of chronic obstructive pulmonary disease(COPD) and featured by abnormally high pulmonary artery pressure. With the exacerbation of pulmonary vasoconstriction and the progression of pulmonary artery remodeling, PH can finally result in right heart failure and even death, worsening the prognosis and increasing the mortality of COPD patients^{[1][2]}, but the pathogenesis of the disease has not been fully elucidated. As a devastating cardiopulmonary disease, PH exhibits many cancer-like characteristics, including sustained cell proliferation and apoptosis resistance of pulmonary vascular cells such as pulmonary arterial endothelial cells(HPAECs), pulmonary arterial smooth muscle cells (HPASMCs) and fibroblasts, dysregulated cellular metabolism and endothelial-to-mesenchymal transition (EndoMT)^{[3][4]}. Although efforts have been made to develop targeted drug therapies and interventional therapies, existing treatments can't brought enough therapeutic benefits as expected, due to which the prognosis of COPD-PH patients remains disappointing^[5]. Therefore, it is crucial that COPD-PH patients be diagnosed at an early stage, and novel diagnostic biomarkers and molecular targets be explored to bring light into the mechanism of COPD-PH.

In recent years, researches have found that circular RNA(circRNA) participates in the initiation and development of PH. CircRNA is a type of single-stranded RNA molecular with covalently closed loop structures. Compared to traditional linear RNA, circRNA is more stable, conserved and tissue-specific. Among all the functions, the best demonstrated function of circRNA is miRNA sponging. CircRNA can act as a sponge of the targeted miRNA and regulate its activity by repressing its expression, subsequently modulating the expression of their downstream target genes^[6-7]. Recent studies have shown that circRNA is closely related to the occurrence and development of multiple diseases and have the potential to become novel diagnostic biomarkers as well as therapeutic targets for these diseases, including different sorts of cancer^[8-11]. There is

evidence that circRNAs are also involved in the pathogenesis of PH in COPD. Zhou et al.^[12] found that circHIPK3 promotes the proliferation of HPAECs and induces angiogenesis via the miR-328-3p/STAT3. Additionally, hsa_circNFXL1_009 was reported to attenuate hypoxia-induced proliferation, apoptotic resistance, and migration of HPASMCs^[13]. These researches indicate that circRNAs participate in the pathogenesis of PH in COPD by regulating the biological behaviour of pulmonary vascular cells. However, circRNA-related studies on PH in COPD patients are inadequate, on account of which, the underlying role of circRNA in COPD-PH has not been comprehensively explained.

Bioinformatics tools has been widely applied in oncology to identify genetic changes and new potential biomarkers associated with various diseases^[14-16]. Likewise, researchers have tried to apply bioinformtics analysis in the study of PH to to elucidate the potential functions of circRNAs related to PH, mostly based on databases and animal experiments^[17-26]. However, few studies have utilized clinical samples with definite diagnosis of PH, and researches for PH in COPD are even fewer. To the best of our knowledge, the present study is the first to profile circRNA expression of lung tissues from COPD patients with mean pulmonary artery pressure(mPAP) ≥ 20 mmHg measured by right heart catheterization(RHC)^[27]. 136 differentially expressed circRNAs were identified between the COPD-PH and control groups. Subsequently, we validated the most 10 dysregulated circRNAs in patients' serum and hypoxia-induced vascular cells by quantitative real-time polymerase chain reaction (qRT-PCR). Functional enrichment analyses were carried out to investigate the main functional pathways involved in the development of PH in COPD. After the prediction of miRNAs and mRNAs for candidate circRNAs, a circRNA-miRNA-mRNA interaction network was constructed. Our study identified 2 pivotal circRNAs which has not been reported and 3 downstream mRNAs, provided new diagnostic biomarkers and therapeutic target, and might further the understanding of molecular mechanism of PH in COPD.

Materials and Methods

Ethics

The study procedure was approved by the Medical Ethics Committee of the Affiliated Wuxi People's Hospital of Nanjing Medical University. All patients included in this study have signed the corresponding informed consent.

Sample collection

We selected a total of 12 patients (6 patients were with COPD-PH and 6 patients without PH nor COPD, all patients underwent lung transplantation at Wuxi People's Hospital Affiliated to Nanjing Medical University from January 2020 to December 2020). Lung tissue samples were collected from COPD-PH and control group. We also collected blood samples from COPD-PH patients (n=12, COPD-PH) and patients without PH nor COPD (n=12, control) for further validation. Blood samples were centrifuged at 4°C, 3000 rpm for 10 min, and the extracted supernatant was stored at -80°C. Clinicopathological characteristics of the whole subjects involved are listed in Table S1.

Patients with COPD were diagnosed by post-bronchodilator forced expiratory volume 1s/forced vital capacity (FEV₁/FVC) ratio lower than 70% and without other lung diseases, such as bronchiectasis, diffuse interstitial lung disease, cystic fibrosis or lung cancer. We collected enrolled patients' RHC data to screen out COPD-PH subjects and selected patients with the mean pulmonary artery pressure (mPAP) ≥ 20 mmHg as subjects^[28]. All patients were excluded from non-COPD-related PH such as congenital heart disease, chronic thromboembolic pulmonary hypertension (CTEPH) and arterial pulmonary hypertension (PAH).

Cell Culture

Human pulmonary arterial endothelial cells (HPAECs) were purchased from ScienCell Research Laboratory and cultured in endothelial culture medium. Pulmonary arterial smooth muscle cells (HPASMCs) were purchased from iCell Research Laboratory cultured in smooth muscle culture medium. Control group cells were cultured at 37°C in a humidified incubator with 5% CO₂ while hypoxia group were incubated in a Tri-Gas Incubator (Heal Force, Shanghai, PR China) with a gas mixture containing 95% N₂, 4% CO₂, 1% O₂. Cells were trypsinized and passaged at 90% confluence, and the studies were performed on cells at passages 3–6.

RNA isolation and quality control

Total RNA was isolated from samples using TRIzol (Invitrogen) according to the manufacturer's protocols. The integrity and concentration of RNA samples were determined with

Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA) and Nanodrop (Wilmington, DE, USA). RNA samples satisfied with the following parameters: OD_{260/280} between 1.8 and 2.1, OD_{260/280} >1.8, were subjected to the subsequent analysis.

Library construction and circRNA data analysis

A total of 5μg RNA from samples was used as input material for the RNA sample preparations. The extracted RNA was treated with Epicentre Ribozero™ rRNA Removal Kit(Epicentre, USA) and RNase R (Epicentre, USA) to remove ribosomal and linear transcripts respectively. Sequencing libraries were generated using NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina® (NEB, USA) according to the manufacturer's protocol. End products were purified by AMPure XP system and library was assessed for quality and quantified on the Agilent Bioanalyzer 2100 system(Agilent Technologies, Santa Clara, CA, USA). Qualified reads were mapped against human genome references using find_circ and CIRI^[29-30]. Subsequently, the circRNA expression profiles between the two groups were evaluated using fold-change filtering and t-test, with statistical significance defined by fold-change value of ≥ 2.0 and a P-value of <0.05. The sequencing procedures and analyses were performed by Novogene Biotech(Beijing, China).

Quantitative Real-Time Polymerase Chain Reaction Validation (qRT-PCR) Validation

To further validate the RNA-Seq results, the top 10 DECs and three hub mRNAs were selected for qRT-PCR analysis. Two circRNA primers were not successfully designed, and they were removed in the following experiment. The specific primers of each circRNA is designed according to the sequenced by Sangon Biotech (Shanghai, China). Primers were presented in Table 1. Total RNA was extracted as mentioned above, the cDNA was synthesized from 1000ng of extracted RNA using PrimeScript™RT reagent Kit (Takara, Japan). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using TB Green™ Premix Ex TaqII (Takara, Japan) on an ABI PRISM 7500 Real Time PCR System (Applied Biosystems, Foster City, CA, USA) with the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an internal control. The PCR conditions were 95°C for 30 min, followed by 40 cycles of 95°C for 5 s and 60°C for 34s. The $2^{-\Delta\Delta t}$ method was used to determine the relative quantification of gene expression levels. The qRT-qPCR for each target gene was repeatedly performed in triplicate^[31].

Table 1. Primers of validated circRNAs.

| Name | Forward | Reverse |
|------------------|---------------------------------|---------------------------------|
| GAPDH | 5'-GTTGTCTCCTGCGACTTCA-3' | 5'-GCCCCCTCCTGTTATTATGG-3' |
| hsa_circ_0007608 | 5'-GAGGCCCCGATTCATCAACCA-3' | 5'-TTGGGGGAACACTCAGCAAA-3' |
| hsa_circ_0076410 | 5'-ATCAGCTGACCCAGCCAAAC-3' | 5'-TCTCCAAGCTGGTTGCTTACA-3' |
| hsa_circ_0007121 | 5'-CGGCAAGCTTCCCATAGACA-3' | 5'-AGGGGAAAAATAGTCCTCACAGA-3' |
| hsa_circ_0011572 | 5'-CAGAGCACCTCAGCACCATA-3' | 5'-GTTGAGTGCTGGGCGTAGTA-3' |
| hsa_circ_0026227 | 5'-TCCCAATTTGGACAGTTGCC-3' | 5'-GAGTTACTGGGGTGGCATCA-3' |
| hsa_circ_0019061 | 5'-TCATGTTGCCAGAGGCCATT-3' | 5'-CTTGCTTAGGGCACGGACTC-3' |
| hsa_circ_0086483 | 5'-GGGTAGGTTCAAGGTGGTGG-3' | 5'-AGGGTTGCATGGAAGTAGACG-3' |
| hsa_circ_0064656 | 5'-GAGTCCTTCAAGCAGACCGA-3' | 5'-TGTCAGAGCGGTCATCTTCC-3' |
| VCAM1 | 5'-GGATTGCTGCTCAGATTGGAGACTC-3' | 5'-CACTCCTCACCTTCCCGCTCAG-3' |
| VCAN | 5'-CCATCTCACAAGCATCCTGTCTCAC-3' | 5'-CTGCCATCAGTCCAACGGAAGTC-3' |
| THBS1 | 5'-AACTGTCCCTATGTGCCCAATGC-3' | 5'-TGTCATCAGGAATGCCATCGTTGTC-3' |

Prediction of target miRNAs and mRNAs and construction of circRNA-miRNA-mRNA network

Previous studies have verified that circRNA contains miRNA response elements (MREs) and can function as miRNA sponges to regulate their potential functions through competing endogenous RNA (ceRNA). To further clarify the role of circRNAs in COPD-PH, we chose 10 circRNAs with the most obvious expression difference, including five up-regulated and five down-regulated circRNAs, and predicted the miRNA and mRNAs targets of these circRNAs based on Miranda(www.miranda.org/) and TargetScan(www.targetscan.org/) application^[32]. Then a circRNA-miRNA-mRNA network was constructed by Cytoscape software (version 3.2.0; <https://cytoscape.org/>).

Bioinformatics analysis

The function of the target genes were further analyzed by using Gene Ontology (<http://www.geneontology.org>) and were classified into three domains: biological process (BP), molecular function (MF) and cellular component (CC). GO terms with corrected P-value less than 0.05 were considered to be significantly enriched in differential expressed genes. In addition, Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/>) was used to

identify the biological pathways of target genes. Gene Ontology annotation and KEGG analysis were undertaken using an R package named clusterProfiler^[33].

Establishment of the Protein-Protein Interaction (PPI) Network

We acquired data of key mRNAs and constructed the PPI network via STRING database (<https://string-db.org/>). Then construct a PPI network using Cytoscape^[34]. Then we used the Cytohuba, a Cytoscape plugin to rank the 11 pairs of mRNAs according to degree and the correlation with HPH to screen out hub genes.

Statistical analysis

All of the statistical analyses were performed using GraphPad Prism v6.01 (GraphPad Software, CA, USA), R Studio version 3.2.1 (<http://www.r-project.org/>) and Microsoft Excel (Microsoft, DC, USA). The difference between 2 groups were assessed by Student's t-test. P-value <0.05 was considered as statistically significant.

Results

Analysis of circRNA expression profile in COPD-PH patients

In our RNA sequence, a total of 11193 circRNAs were identified in two groups of samples.

All data were analyzed according to the work flow (Fig 1).




Figure 1 The workflow of study.

Abbreviations: GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; PPI, protein-protein interaction.

A box plot of the normalized expression of gene in all samples showed the credibility of our data (Figure 2A). A cluster heatmap of the differentially was used to assess the expression variation of circRNAs between two groups (Figure 2B), in which the high and low expression of circRNAs were marked in red and green respectively. A volcano plot(Figure 2C) and a scatter plot (Figure 2D) were constructed to visualize the differential expression of circRNAs between the two groups. In total, 136 DECs were identified between the COPD-PH and control groups, of

which 39 circRNAs were up-regulated and 97 circRNAs were down-regulated. The top 10 DECs are listed in Table 2.

Figure 2. Microarray analysis of differential expression of circRNAs in COPD-PH patients. (A) A box plot of gene expression in all samples. (B) Hierarchical cluster analysis revealed the expression profile of the dysregulated circRNAs in the two groups. (C) Volcano map of differentially expressed circRNAs in COPD-PH group. The two vertical lines show differentially expressed circRNAs of 2-fold up and down, and the horizontal line represents $p=0.05$. Green dots and red dots indicate circRNAs that were differentially expressed with statistical significance. (D) Scatter plot demonstrates the expression variation of circRNAs in the two groups. The values of x and y-axes represent the normalized values of the samples (\log_2 scaled). The red dots outside the top grey line indicate the up-regulated circRNAs with ≥ 2 -fold change and the green dots outside bottom grey line indicate the down-regulated circRNAs with ≥ 2 -fold change.

Table 2. The top 10 differentially expressed circRNAs with the most significant difference in the COPD-PH.

| ID | \log_2 FoldChange | P value | Regulation | Gene Symbol |
|--------------------|---------------------|---------|------------|-------------|
| hsa_circ_0007608 | 4.7324 | 0.010 | Up | ASH1L |
| hsa_circ_0076410 | 4.4304 | 0.003 | Up | KIAA0240 |
| hsa_circ_0007121 | -4.3541 | 0.001 | Down | RAPGEF2 |
| hsa_circ_0011572 | 4.3441 | 0.002 | Up | KIAA0319L |
| hsa_circ_0026227 | 4.2864 | 0.007 | Up | LARP4 |
| hsa_circ_0019061 | -4.1324 | 0.002 | Down | STAMBPL1 |
| hsa_circ_0086483 | -4.0534 | 0.004 | Down | ACER2 |
| novel_circ_0011203 | 4.0491 | 0.017 | Up | CYP1B1-AS1 |
| hsa_circ_0064656 | 4.0313 | 0.018 | Up | TGFBR2 |
| novel_circ_0015824 | 3.9487 | 0.027 | Up | ZSCAN26 |

qRT-PCR validation of circRNAs expression

We selected the top 10 most DECs based on the circRNA expression profiles for further validation in 12 pairs of subjects' serum. Two circRNA primers were not successfully designed, and they were removed in the following experiment. The circRNAs involved in the validation included five up-regulated circRNAs (including hsa_circ_0007608, hsa_circ_0076410, hsa_circ_0011572, hsa_circ_0026227, hsa_circ_0064656) and three down-regulated circRNAs (including hsa_circ_0007121, hsa_circ_0019061, hsa_circ_0086483). Analysis by qRT-PCR confirmed three up-regulated circRNAs in serum, which were consistent with the results of the circRNA microarray. More specifically, it was found that hsa_circ_0007608, hsa_circ_0076410 and hsa_circ_0064656 were significantly up-regulated in COPD-PH group compared with that in

control group (Figure 3A-B). Furthermore, we found the expression of hsa_circ_0007608 was constantly up-regulated with the prolongation of hypoxia in HPAECs (Figure 3C), which is consistent with the results verified in serum. Interestingly, hsa_circ_0064656 was confirmed to express differently in different cells. When chronic hypoxia occurs in pulmonary vascular cells, hsa_circ_0064656 decreased significantly in HPAECs (Figure 3D), while increased in HPASMCs (Figure 3E). This phenomenon suggests that hsa_circ_0064656 may be involved in the intercellular signal transduction between HPAECs and HPASMCs in pulmonary vessels under hypoxia microenvironment during COPD-PH pathogenesis.

Figure 3. qRT-PCR validation of circRNAs expression in serum and pulmonary vascular cell. (A-B) Two significantly up-regulated circRNAs in serum. (C) hsa_circ_0007608 was constantly up-regulated with the prolongation of hypoxia in HPAECs. (E, F) hsa_circ_0064656 decreased significantly in HPAECs, while increased in HPASMCs (* $P < 0.05$, *** $P < 0.001$).

Identification of key miRNAs based on interaction of predicted miRNAs and DE miRNAs

CircRNAs have been known to sponge miRNAs, leading to the derepression of miRNA targets and act as 'miRNA sponges' within the cellular RNA network. We selected the two most dysregulated circRNAs and then mapped them with the miRanda database to obtain the targeted miRNA of the circRNA. We screened out a total of 13 miRNAs and 4099 target mRNAs of miRNAs were identified via online databases (Table S2).

As mentioned above, we also evaluated differentially expressed mRNAs (DE mRNAs) between the two groups. A cluster heatmap (Figure 4A) and a volcano plot (Figure 4B) were used to show the differential expression of mRNAs between the two groups. In order to find the key mRNAs involved in COPD-PH pathogenesis more accurately, we selected 35 mRNAs through the interaction analysis with target mRNAs and DE mRNAs (Figure 4C). Finally, the regulatory network of two circRNAs, 13 miRNAs and 35 mRNAs was constructed (Figure 4D).

Figure 4 (A) Cluster heatmap revealed the expression profile of the dysregulated mRNAs in the two groups. (B) Volcano map of differentially expressed mRNAs in COPD-PH group. (C) A Venn of target mRNA and

DEmRNA. (D) The circRNA-miRNA-mRNA regulatory network. circRNA, miRNA, and mRNA are indicated by red triangles, blue diamonds and green squares, respectively.

Functional and pathway enrichment analysis/GO and KEGG analyses for circRNA-targeting genes

In order to accurately predict the key role of circRNA in the pathogenesis of COPD-PH, the linear transcripts of the corresponding genes of the target of circRNA were further evaluated through GO and KEGG pathway analysis. The GO analysis results from the Biological Process, Cellular Component and Molecular Function domains (Figure 5). The top 10 dysregulated GO processes in each domain were analyzed and ranked according to p-value ($p < 0.05$). The top 3 enriched GO terms were regulation of intracellular signal transduction, regulation of phosphate metabolic process, regulation of phosphorus metabolic process in BP; extracellular matrix (ECM), interphotoreceptor matrix and extracellular region part in CC; calcium ion binding, metalloendopeptidase activity and ion binding in MF.

Figure 5. A bar plot of top 10 GO enriched biological process, cellular component and molecular process of linear counterparts of DECs in COPD-PH. The $-\log_{10}$ (p-value) yields an enrichment score representing the significance of GO term enrichment between differently expressed circRNAs.

KEGG pathway enrichment analysis was also carried out to explore potential biological processes and pathways enriched by the target genes of circRNAs. The top 5 enriched KEGG pathways included NF-kappa B signaling pathway, Malaria, TGF-beta signaling pathway, MAPK signaling pathway and TNF signaling pathway (Figure 6).

Figure 6. A dot plot of top 10 KEGG pathway of linear counterparts of DECs in COPD-PH. KEGG analysis according to rich factor, q-value and the number of enriched genes.

Identification and validation of Hub mRNAs

To determine the interactions between the downstream mRNAs of hsa_circ_0007608 and hsa_circ_0064656 and identify hub genes in COPD-PH, We further made correlation analysis of 35 key mRNA (Figure 7A). Among them, 11 pairs of protein interactions were screened according to the reliability greater than 0.40 (Figure 7B). We continued to analyze the correlation between these key mRNAs and COPD-PH, and finally screened three hub mRNAs with high reliability

greater than 0.9 and closely related to COPD-PH. They included vascular cell adhesion molecule 1 (VCAM1), versican (VCAN), thrombospondin 1 (THBS1). Furthermore, we verified the three hub mRNAs in two kinds of pulmonary vascular cells by qRT-PCR, and proved that the expression of these three hub mRNAs was indeed up-regulated in pulmonary vessels (Figure 7C-H).

Figure 7 (A) Correlation heat map of 35 key mRNA. (B) The protein-protein interaction (PPI) of key mRNAs. (C-E) VCAM1, VCAN and THBS1 were up-regulated in HPAECs. (F-H) VCAM1, VCAN and THBS1 were up-regulated in HPASMCs. (**P<0.01, *** P<0.001)

Discussion

Statistically, the mortality rate of COPD patients with severe PH is around 12% per year, which reflects that PH worsen the prognosis of COPD patients in large measure^[35]. New therapeutic strategies have been explored for the treatment of PH in patients with COPD, but most targeted PH therapies are limited in clinical application. According to previous studies, dysfunction of pulmonary vascular cells including HPAECs, HPASMCs and fibroblasts may play important roles in mediating PH in COPD. But the underlying mechanism of PH in COPD has not been clarified completely. With the rapid advances in gene sequencing technologies, several studies have identified some dysregulated circRNAs in PH, mostly based on animal experiments and public databases. However, there is still a lack of studies depending on clinical samples, and bioinformatics analysis on PH in COPD is rare. To achieve the high clinical value, we screened out the DECs from 12 human lung tissues. In this research, we identified 136 DECs between the COPD-PH and control groups, of which 39 circRNAs were up-regulated and 97 circRNAs were down-regulated, and the top ten dysregulated circRNAs were then validated by qRT-PCR in patients' serum, HPAECs and HPASMCs. According to validation, hsa_circ_0007608 and hsa_circ_0064656 were selected for further analysis.

It is noteworthy that those two circRNAs have not been reported in any studies on PH so far, so that functional and pathway enrichment analysis was conducted to better understand their possible functions in COPD-PH. GO analysis manifested that hsa_circ_0007608 and hsa_circ_0064656 were chiefly enriched in the regulation of intracellular signal transduction, ECM and calcium ion binding. KEGG pathway results revealed that they were markedly enriched in NF- κ B signaling pathway, malaria, TGF- β signaling pathway, MAPK signaling pathway and

TNF signaling pathway. As shown in previous reports, the GO terms and KEGG pathways that hsa_circ_0007608 and hsa_circ_0064656 were enriched in were all related to the occurrence and regulation processes of PH. It is obvious that intracellular signal transduction is ubiquitous in the pathogenesis of PH in COPD^[36]. Existing studies also show that ECM is implicated in the development of pulmonary vascular remodeling and high level of ECM-related proteins such as MMP-2 are associated with poor survival and prognosis of PH patients^[37]. Additionally, release of calcium ions from the endoplasmic reticulum to the cytoplasm and mitochondria is an important mediators of cell proliferation, migration and mesenchymal transition, thereby affecting the contractility and resistance of pulmonary artery^[38-39]. As inflammation mediators, NF- κ B, TGF- β , MAPK and TNF can regulate the functions of pulmonary vascular cells, including cellular proliferation, apoptosis and migration, contributing to pulmonary vascular remodeling^[40-43]. Interestingly, those 4 cytokines mentioned above also can induce or participate in the conversion process of endothelial cells into mesenchymal fibroblast-like cells that is an important pathologic change of pulmonary vascular remodeling. More specifically, NF- κ B, a cellular transcription factor regulating inflammation, plays a central role in inflammation-mediated EndoMT, the stimulation of which and the subsequent production of cytokines is the key step in EndoMT^[44]. TGF- β is the main inducer of EndoMT, and the pathways through which TGF- β induced EndoMT include MAPK^[45-46]. In addition, TNF, the most significant pro-inflammatory cytokines released during inflammation, is also related to the induction of EndoMT^[47]. However, little is known about the correlation between malaria and the occurrence of PH in COPD, which needs further exploration. Combined with the above, the difference of hsa_circ_0064656 changing trends between the hypoxic HPAECs and HPASMCs could be attributed to the different roles these two cells play in EndoMT under hypoxic condition. Taken together, we hypothesized that hsa_circ_0007608 and hsa_circ_0064656 might serve as key regulators in the pathogenesis of COPD-PH through these enriched pathways, especially through the regulation of EndoMT, and possess the potential to become novel therapeutic targets, although the detailed biological mechanisms of those circRNAs and the interactions between the DECs and their target miRNAs need future in-depth studies.

Based on the prediction of downstream miRNAs and mRNAs, we constructed a circRNA-miRNA-mRNA regulatory network of the two validated DECs. Combined with the construction

of PPI network and the qRT-PCR results, 3 hub genes including VCAM1, THBS1 and VCAN were recognized. According to previous reports, VCAM1, THBS1 contributes to the progression of pulmonary vascular remodeling. As a member of the immunoglobulin superfamily, VCAM1 contributes to endothelial dysfunction and is related with the inflammation of HPAECs^[47-48]. Study has also identified that THBS1 participates in the occurrence and development of PH^[49-50]. So far, there is no research to illustrate the role of VCAN in PH, indicating that VCAN might be a new discovery for PH and merits further exploration. Overall, the above results demonstrate that the ceRNA network are possibly involved in the pathogenesis of PH in COPD patients and may become novel diagnostic biomarkers and therapeutic targets for COPD-PH.

However, there are still a number of limitations in our study. Most of our results were based on computational prediction, which need further validation by molecular biological experiments. Besides, although cell experiments was performed to verify the reliability of the sequencing results, our study lacks vivo experiments to further validate these results. Another limitation of the present study is the small sample size. Therefore, our findings await more comprehensive analyses and further in-depth studies to provide accurate evidence for prognostic and diagnostic biomarkers in COPD-PH.

Conclusion

To summarize, our study revealed the expression profile of circRNAs in COPD-PH patients, and established a circRNA-miRNA-mRNA interaction network. We discovered that hsa_circ_0007608 and hsa_circ_0064656 are the most notable markers of PH in COPD and may be regarded as potential targets for the treatment of COPD-PH. Moreover, VCAM1, THBS1 and VCAN are identified as the most reliable key mRNAs, of which VCAN might be a new discovery for the molecular mechanism of COPD-PH. These findings will provide bioinformatics basis for further research into the molecular mechanism of pulmonary hypertension in COPD patients and provide novel insight into the development of targeted drug therapy and diagnostic biomarkers.

Data Availability statement

All data generated or analyzed during this study are included in this published article and its supplementary information files. The datasets generated or analysed during the current study are available in the Sequence Read Archive (SRA) database of NCBI, [<https://www.ncbi.nlm.nih.gov/sra/PRJNA913650>].

Ethics Approval and Consent to Participate

All experimental work was approved by the ethical review board of Wuxi People's Hospital Affiliated to Nanjing Medical University. This study was conducted in accordance with the tenets of the Declaration of Helsinki. The procedures were approved by the Ethics Committee of Nanjing Medical University (KY21033).

Author Contributions

All authors made a significant contribution to the work reported, whether in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all of these areas. All authors took part in drafting, revising or critically reviewing the article, gave final approval of the version to be published, have agreed on the journal to which the article has been submitted and agree to be accountable for all aspects of the work.

Funding

This work was supported by the Natural Science Foundations of China (82173472), the Top Talent Support Program for young and middle-aged people of Wuxi Health Committee (BJ2020006) and General Program of Wuxi Health Committee (M202032).

Disclosure

The authors declare that they have no competing interests.

References

- [1] Blanco I, Tura-Ceide O, Peinado VI, Barberà JA. Updated Perspectives on Pulmonary Hypertension in COPD. *Int J Chron Obstruct Pulmon Dis*. 2020;15:1315-1324. Published 2020 Jun 9.
- [2] Vizza CD, Hoeper MM, Huscher D, et al. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). *Chest*. 2021;160(2):678-689.
- [3] Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. *Eur Respir J*. 2019;53(1):1801887. Published 2019 Jan 24.
- [4] Woo KV, Shen IY, Weinheimer CJ, et al. Endothelial FGF signaling is protective in hypoxia-induced pulmonary hypertension. *J Clin Invest*. 2021;131(17):e141467. doi:10.1172/JCI141467


- [5] Maron BA, Abman SH, Elliott CG, et al. Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. *Am J Respir Crit Care Med*. 2021;203(12):1472-1487.
- [6] Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. *Nat Rev Genet*. 2019;20(11):675-691.
- [7] Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. *Nature*. 2013;495(7441):384-388.
- [8] van Zonneveld AJ, Kölling M, Bijkerk R, Lorenzen JM. Circular RNAs in kidney disease and cancer. *Nat Rev Nephrol*. 2021;17(12):814-826.
- [9] Wei G, Zhu J, Hu HB, Liu JQ. Circular RNAs: Promising biomarkers for cancer diagnosis and prognosis. *Gene*. 2021;771:145365.
- [10] Almouh M, Razmara E, Bitaraf A, Ghazimoradi MH, Hassan ZM, Babashah S. Circular RNAs play roles in regulatory networks of cell signaling pathways in human cancers [published online ahead of print, 2022 Sep 17]. *Life Sci*. 2022;120975.
- [11] Zeng X, Xiao J, Bai X, et al. Research progress on the circRNA/lncRNA-miRNA-mRNA axis in gastric cancer [published online ahead of print, 2022 Jul 19]. *Pathol Res Pract*. 2022;238:154030.
- [12] Hong L, Ma X, Liu J, et al. Circular RNA-HIPK3 regulates human pulmonary artery endothelial cells function and vessel growth by regulating microRNA-328-3p/STAT3 axis. *Pulm Circ*. 2021;11(2):20458940211000234. Published 2021 Mar 29. doi:10.1177/20458940211000234
- [13] Jin X, Xu Y, Guo M, et al. hsa_circNFXL1_009 modulates apoptosis, proliferation, migration, and potassium channel activation in pulmonary hypertension. *Mol Ther Nucleic Acids*. 2020;23:1007-1019. Published 2020 Sep 28. doi:10.1016/j.omtn.2020.09.029
- [14] Yin L, Tang Y, Yuan Y. An Overview of the Advances in Research on the Molecular Function and Specific Role of Circular RNA in Cardiovascular Diseases. *Biomed Res Int*. 2022;2022:5154122.
- [15] Pan S, Chen Y, Yan J, et al. The emerging roles and mechanisms of exosomal non-coding RNAs in the mutual regulation between adipose tissue and other related tissues in obesity and metabolic diseases. *Front Endocrinol (Lausanne)*. 2022;13:975334.
- [16] Zhang L, Wang C, Lu X, Xu X, Shi T, Chen J. Transcriptome sequencing of hepatocellular carcinoma uncovers multiple types of dysregulated ncRNAs. *Front Oncol*. 2022;12:927524.


- [17] Zheng H, Hua J, Li H, et al. Comprehensive analysis of the expression of N6-methyladenosine RNA methylation regulators in pulmonary artery hypertension. *Front Genet.* 2022;13:974740. Published 2022 Sep 12. doi:10.3389/fgene.2022.974740
- [18] Han X, Li C, Yang P, Jiang T. Potential mechanisms of Qili Qiangxin capsule to prevent pulmonary arterial hypertension based on network pharmacology analysis in a rat model. *Ann Transl Med.* 2022;10(8):453. doi:10.21037/atm-22-901
- [19] Wang J, Uddin MN, Wang R, Gong YH, Wu Y. Comprehensive analysis and validation of novel immune and vascular remodeling related genes signature associated with drug interactions in pulmonary arterial hypertension. *Front Genet.* 2022;13:922213. Published 2022 Sep 6. doi:10.3389/fgene.2022.922213
- [20] Wei RQ, Zhang WM, Liang Z, Piao C, Zhu G. Identification of Signal Pathways and Hub Genes of Pulmonary Arterial Hypertension by Bioinformatic Analysis. *Can Respir J.* 2022;2022:1394088. Published 2022 Aug 29. doi:10.1155/2022/1394088
- [21] Wang RR, Yuan TY, Chen D, et al. Dan-Shen-Yin Granules Prevent Hypoxia-Induced Pulmonary Hypertension via STAT3/HIF-1 α /VEGF and FAK/AKT Signaling Pathways. *Front Pharmacol.* 2022;13:844400. Published 2022 Mar 11. doi:10.3389/fphar.2022.844400
- [22] Tang S, Liu Y, Liu B. Integrated bioinformatics analysis reveals marker genes and immune infiltration for pulmonary arterial hypertension. *Sci Rep.* 2022;12(1):10154. Published 2022 Jun 16. doi:10.1038/s41598-022-14307-6
- [23] Tu J, Jin J, Chen X, Sun L, Cai Z. Altered Cellular Immunity and Differentially Expressed Immune-Related Genes in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. *Front Immunol.* 2022;13:868983. Published 2022 May 18. doi:10.3389/fimmu.2022.868983
- [24] Lin W, Tang Y, Zhang M, et al. Integrated Bioinformatic Analysis Reveals TXNRD1 as a Novel Biomarker and Potential Therapeutic Target in Idiopathic Pulmonary Arterial Hypertension. *Front Med (Lausanne).* 2022;9:894584. Published 2022 May 12. doi:10.3389/fmed.2022.894584
- [25] Wang S, Liu Y, Wang Q, et al. Utilizing Network Pharmacology and Molecular Docking Integrated Surface Plasmon Resonance Technology to Investigate the Potential Targets and Mechanisms of *Tripterygium wilfordii* against Pulmonary Artery Hypertension. *Evid Based*


- Complement Alternat Med. 2022;2022:9862733. Published 2022 Apr 30.
doi:10.1155/2022/9862733
- [26] Wei R, Chen L, Li P, Lin C, Zeng Q. IL-13 alleviates idiopathic pulmonary hypertension by inhibiting the proliferation of pulmonary artery smooth muscle cells and regulating macrophage infiltration. *Am J Transl Res*. 2022;14(7):4573-4590. Published 2022 Jul 15.
- [27] Manek G, Gupta M, Chhabria M, Bajaj D, Agrawal A, Tonelli AR. Hemodynamic indices in pulmonary hypertension: a narrative review. *Cardiovasc Diagn Ther*. 2022;12(5):693-707. doi:10.21037/cdt-22-244.
- [28] Ko FW, Yan BP, Lam YY, Chu JH, Chan KP, Hui DS. Undiagnosed airflow limitation is common in patients with coronary artery disease and associated with cardiac stress. *Respirology*. 2016;21(1):137-142. doi:10.1111/resp.12668
- [29] Lee H, Lee KW, Lee T, Park D, Chung J, Lee C, Park WY and Son DS. Performance evaluation method for read mapping tool in clinical panel sequencing. *Genes Genomics* 2018; 40: 189-197.
- [30] Li Y, He S, He A, et al. Identification of plasma secreted phosphoprotein 1 as a novel biomarker for upper tract urothelial carcinomas. *Biomed Pharmacother*. 2019;113:108744. doi:10.1016/j.biopha.2019.108744
- [31] Song H, Liu Y, Jin X, et al. Long non-coding RNA LINC01535 promotes cervical cancer progression via targeting the miR-214/EZH2 feedback loop. *J Cell Mol Med*. 2019;23(9):6098-6111. doi:10.1111/jcmm.14476
- [32] Yan Y, Zhang R, Zhang X, et al. RNA-Seq profiling of circular RNAs and potential function of hsa_circ_0002360 in human lung adenocarcinoma. *Am J Transl Res*. 2019;11(1):160-175. Published 2019 Jan 15.
- [33] Wang J, Zhu MC, Kalionis B, et al. Characteristics of circular RNA expression in lung tissues from mice with hypoxia-induced pulmonary hypertension. *Int J Mol Med*. 2018;42(3):1353-1366. doi:10.3892/ijmm.2018.3740
- [34] Huang XF, Zhang JL, Huang DP, et al. A network pharmacology strategy to investigate the anti-inflammatory mechanism of luteolin combined with in vitro transcriptomics and proteomics. *Int Immunopharmacol*. 2020;86:106727. doi:10.1016/j.intimp.2020.106727

- [35] Vizza CD, Hoeper MM, Huscher D, et al. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). *Chest*. 2021;160(2):678-689. doi:10.1016/j.chest.2021.02.012
- [36] Wei RQ, Zhang WM, Liang Z, Piao C, Zhu G. Identification of Signal Pathways and Hub Genes of Pulmonary Arterial Hypertension by Bioinformatic Analysis. *Can Respir J*. 2022;2022:1394088. Published 2022 Aug 29. doi:10.1155/2022/1394088
- [37] Arvidsson M, Ahmed A, S  leby J, Hesselstrand R, R  degran G. Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension. *Pulm Circ*. 2022;12(1):e12041. Published 2022 Feb 4. doi:10.1002/pul2.12041
- [38] Guo X, Meng Y, Wang Y, et al. Mice lacking 1,4,5-triphosphate inositol type III receptor demonstrate inhibition of hypoxic pulmonary hypertension. *Biochem Biophys Res Commun*. 2022;629:165-170. doi:10.1016/j.bbrc.2022.09.036
- [39] Gabani M, Liu J, Ait-Aissa K, et al. MiR-204 regulates type 1 IP3R to control vascular smooth muscle cell contractility and blood pressure. *Cell Calcium*. 2019;80:18-24. doi:10.1016/j.ceca.2019.03.006
- [40] P  rez L, Mu  oz-Durango N, Riedel CA, et al. Endothelial-to-mesenchymal transition: Cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions. *Cytokine Growth Factor Rev*. 2017;33:41-54. doi:10.1016/j.cytogfr.2016.09.002
- [41] Silva GF, da Silva JS, de Alencar AKN, et al. Novel p38 Mitogen-Activated Protein Kinase Inhibitor Reverses Hypoxia-Induced Pulmonary Arterial Hypertension in Rats. *Pharmaceuticals (Basel)*. 2022;15(7):900. Published 2022 Jul 21. doi:10.3390/ph15070900
- [42] Pugliese SC, Poth JM, Fini MA, Olschewski A, El Kasmi KC, Stenmark KR. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. *Am J Physiol Lung Cell Mol Physiol*. 2015;308(3):L229-L252. doi:10.1152/ajplung.00238.2014
- [43] Maleszewska M, Moonen JR, Huijman N, van de Sluis B, Krenning G, Harmsen MC. IL-1 β and TGF β 2 synergistically induce endothelial to mesenchymal transition in an NF κ B-dependent manner. *Immunobiology*. 2013;218(4):443-454. doi:10.1016/j.imbio.2012.05.026

- [44] Chen PY, Qin L, Baeyens N, et al. Endothelial-to-mesenchymal transition drives atherosclerosis progression. *J Clin Invest*. 2015;125(12):4514-4528. Published 2015 Oct 26. doi:10.1172/JCI82719
- [45] Pérez L, Muñoz-Durango N, Riedel CA, et al. Endothelial-to-mesenchymal transition: Cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions. *Cytokine Growth Factor Rev*. 2017;33:41-54. doi:10.1016/j.cytogfr.2016.09.002
- [46] Adjuto-Saccone M, Soubeyran P, Garcia J, et al. TNF- α induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma. *Cell Death Dis*. 2021;12(7):649. Published 2021 Jun 25. doi:10.1038/s41419-021-03920-4
- [47] Jang AJ, Chang SS, Park C, et al. PPAR γ increases HUWE1 to attenuate NF- κ B/p65 and sickle cell disease with pulmonary hypertension. *Blood Adv*. 2021;5(2):399-413. doi:10.1182/bloodadvances.2020002754
- [48] Iranmehr A, Stobdan T, Zhou D, et al. Novel insight into the genetic basis of high-altitude pulmonary hypertension in Kyrgyz highlanders. *Eur J Hum Genet*. 2019;27(1):150-159. doi:10.1038/s41431-018-0270-8
- [49] Kumar R, Mickael C, Kassa B, et al. Interstitial macrophage-derived thrombospondin-1 contributes to hypoxia-induced pulmonary hypertension. *Cardiovasc Res*. 2020;116(12):2021-2030. doi:10.1093/cvr/cvz304
- [50] Moll M, Christmann RB, Zhang Y, et al. Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. *J Scleroderma Relat Disord*. 2018;3(3):242-248. doi:10.1177/2397198318764780







WITHDRAWN

see manuscript DOI for details

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted November 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

WITHDRAWN
see manuscript DOI for details

0.00
0.00
0.00

0.00
0.00

WITHDRAWN

see manuscript DOI for details







WITHDRAWN
see manuscript DOI for details




WITHDRAWN

see manuscript DOI for details







target mRNA


DE mRNA


4062


35


152

see manuscript DOI for details









2025.04.15
5107.5107

WITHDRAWN
see manuscript DOI for details



bioRxiv preprint doi: <https://doi.org/10.1101/012121>; this version posted April 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

WITHDRAWN
see manuscript DOI for details



bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

WITHDRAWN

see manuscript DOI for details



bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

WITHDRAWN
see manuscript DOI for details



bioRxiv preprint doi: <https://doi.org/10.1101/2020.05.05.288975>; this version posted May 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

WITHDRAWN

see manuscript DOI for details



bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2016. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

WITHDRAWN
see manuscript DOI for details



Boxplot for FPKM values

